following a full submission assessed under the end of life process:
cabozantinib (Cabometyx®) is not recommended for use within NHSScotland.
Indication under review: advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.
In a phase II study, in treatment-naïve adults with advanced RCC with intermediate or poor risk as defined by the IMDC risk group categories, cabozantinib was superior to another tyrosine kinase inhibitor for progression free survival.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- cabozantinib (Cabometyx)
- SMC ID:
- Treatment of advanced renal cell carcinoma in treatment-naïve adults with intermediate or poor risk per IMDC criteria.
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full submission
- Not recommended
- Date advice published:
- 08 October 2018